START-GAP/DLC Family Proteins: Molecular Mechanisms for Anti-Tumor Activities by Yagisawa, Hitoshi
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






START-GAP/DLC Family Proteins: Molecular
Mechanisms for Anti-Tumor Activities
Hitoshi Yagisawa
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/55268
1. Introduction
The Rho family of GTPases belongs to the superfamily named “Ras-like” proteins, which
consists of over 150 varieties in mammals [1]. Significant progress has recently been made in
understanding the biological functions mediated by this family of small (~21 kDa) G proteins
(guanine nucleotide-binding proteins). Rho GTPases affect crucial biological processes such
as transcriptional regulation, cell cycle progression, apoptosis and membrane trafficking [2,
3]. Thus far, a total of 23 Rho proteins have been identified [4], among which RhoA, Rac1 and
Cdc42 are characterized in detail. Rho GTPases are also involved in the cytoskeleton formation
of the cell via the regulation of actin dynamics [5, 6]. RhoA induces stress fiber formation and
focal adhesion assembly, thereby regulating cell shape, attachment and motility, whereas Rac1
promotes extension of lamellipodia and membrane ruffling [7]. Cdc42 has been shown to play
a role in the formation of filopodia [8].
Like other small G proteins of the Ras-like protein family, Rho GTPases act by switching
between an inactive GDP-bound and an active GTP-bound form, with the latter form capable
of interacting with a myriad of downstream effectors (so far, more than 70 proteins have been
identified [4]) to be activated by them. The activation of Rho GTPases is stimulated by guanine
nucleotide exchange factors (GEFs) that exchange GDP for GTP and is inhibited by GTPase-
activating proteins (GAPs) that hydrolyze the GTP to GDP [9]. Rho GTPases are also negatively
regulated by guanine nucleotide dissociation inhibitors (GDIs), which bind to the GDP-bound
form and not only prevent nucleotide exchange, but also remove Rho GTPases from the plasma
membrane to the cytoplasm [4, 10, 11]. Taken together, cell morphology requires spatiotem‐
porally restricted regulation of Rho GTPases through these regulatory proteins. Nonetheless,
detailed insight into regulation of Rho GTPases has not been provided.
© 2013 Yagisawa; licensee InTech. This is an open access article distributed under the terms of the Creative
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The effect on the wide spectrum of biological functions suggests the involvement of Rho
GTPases and their regulators in cancer progression. Findings from extensive in vitro and in
vivo studies shows that deregulated signaling of Rho GTPases may lead to tumorigenesis [12]
and thus Rho GTPases are taken as potential targeting candidates for cancer therapy [13]. Since
no constitutively active Rho mutants have been reported in human cancers, it is likely that
aberrant Rho GTPase signaling in malignancy is caused by the alterations of their regulators
[4, 12]. Extensive studies so far have revealed that regulators of Rho proteins are over- or
underexpressed in various types of human cancer cells [14-17]. The most common alteration
reported for Rho regulators in cancer is inactivation of RhoGAPs, especially of the START-
GAP/DLC family RhoGAPs [18]. “START” stands for “steroidogenic acute regulatory protein
(STAR)-related lipid transfer” and “DLC” stands for “Deleted in Liver Cancer (DLC),” a gene
(or its product) found to be commonly deleted in liver tumors. The START-GAP/DLC family
proteins have become the focus of attention on their roles in tumorigenesis. This type of genetic
loss was also found in a number of other cancers [17, 19-21].
START-GAP1/DLC1 was originally cloned from rat cDNA library as a binding partner of
phospholipase C-δ1 (PLCδ1) [22]. It has been shown that the C-terminal region of START-
GAP1/DLC1 and the PH domain of PLCδ1 are responsible for the interaction [23, 24]. START-
GAP1/DLC1 enhances the activity of PLCδ1, which generates two second-messengers, inositol
1,4,5-trisphospate (Ins(1,4,5)P3) and diacylglycerol via hydrolysis of phosphatidylinositol 4,5-
bisphosphate (PtdIns(4,5)P2). Ins(1,4,5)P3 is accepted by receptors on ER, resulting the eleva‐
tion of intracellular calcium concentration, whereas diacylglycerol acts as the activator for PKC
[25, 26]. Indeed, microinjection of START-GAP1/DLC1 into the cytosol elevated intracellular
calcium concentration [23].
As mentioned in detail in the following sections, each member of the START-GAP/DLC multi-
domain protein family contains one GAP domain for Rho GTPases. Overexpression of START-
GAP1/DLC1 in cultured cells was first to demonstrate induction of drastic morphological
changes accompanied by the disruption of actin stress fibers and elevation of intracellular
Ca2+ concentrations [23]. START-GAP1/DLC1 was therefore originally designated ARP
(adaptor for both Rho and PLC) [22], but later the name p122RhoGAP (or just p122) was used
to avoid confusion with another ARP (actin related proteins) [23, 24, 27, 28]. We have then
introduced the new name, START-GAP1, based on the characteristic domain structure of this
Rho GTPase family [29-32]. Meanwhile the antioncogenic properties of the protein family have
been revealed and the DLC nomenclature was introduced [21]. In this chapter, the combination
of both the structure- and function-based nomenclatures is used throughout, since the use of
either of them would not be appropriate to reflect the fundamental properties of the protein
family accurately.
In the following sections we will focus on the structure, localization and expression-function
relationship of the START-GAP/DLC family proteins in physiological conditions and in
human diseases.
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2. The START-GAP/DLC gene family
In mammalian genome, there are three genes encoding structurally-related RhoGAPs con‐
taining the START domain (Figure 1). There are three groups of START domain-containing
RhoGAP proteins in vertebrates, while a worm (Caenorhabditis elegans) or a fly (Drosophila
melanogaster) possesses only one START-containing RhoGAP.
Figure 1. A phylogenetic analysis of the START domain-containing RhoGAPs generated with a “Treeview” after CLUS‐
TAL W analysis (http://clustalw.ddbj.nig.ac.jp/). Modified from Kawai et al. [31].
2.1. Human START-GAP/DLC genes and their expression in various tumor cells
There are about 70 human genes encoding RhoGAPs that share a conserved GAP domain and
are capable of switching off the Rho signal [33]. The START-GAP1/DLC1 (also named as
STARD12 or ARHGAP7) gene is localized on chromosome 8p21-22 and encodes a 1,091-amino
acid protein with a molecular mass of 122 kDa. Using the quantitative RT-PCR method, Ko et
al. have reported that START-GAP1/DLC1 is widely expressed in normal tissues, with high
abundance in the lung and ovary, and moderately in the thyroid, spleen, intestine and kidney
[34]. START-GAP1/DLC1 has also been known as a tumor suppressor gene product. It is
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frequently underexpressed or not expressed in several tumor cells and inhibits cell growth,
invasion and metastasis [35, 36]. Studies have indicated that downexpression of START-GAP1/
DLC1 either by genomic deletion or DNA methylation [37] is associated with a variety of cancer
types including lung [38], breast, prostate, kidney, colon, uterus, ovary, and stomach [38] [39]
[40]. These phenotypes require the GAP activity of START-GAP1/DLC1 [35].
Negative regulation of the Rho/Rho-kinase (ROCK)/myosin light chain (MLC) pathway in
hepatocellular carcinoma (HCC) cell lines by START-GAP1/DLC1 was shown to be RhoGAP-
dependent [23, 41, 42]. The RhoGAP defective mutant failed to inhibit stress fiber formation
in HCC lines [41], whereas the overexpression of START-GAP1/DLC1 resulted in morpho‐
logical change with disruption of actin stress fibers [23, 42]. Using various cancer cell models,
START-GAP1/DLC1 was shown to inhibit cell proliferation, suppress cell migration and
invasion, and induce apoptosis [35, 36, 41, 43-45]. Restoration of START-GAP1/DLC1 expres‐
sion in metastatic cell lines has been shown to cause the inhibition of cell migration and
invasion as well as a significant reduction in metastases in nude mice [45].
Underexpression of START-GAP1/DLC1 was associated with either heterozygous deletions
of the START-GAP1/DLC1 gene or hypermethylation of the gene promoter region [17, 37,
46-49]. This protein is therefore thought to be under the epigenetic regulation for expression.
The START-GAP1/DLC1 gene is transcribed from two different promoters, resulting in
transcripts encoding three isoforms [47]. To date, most of studies on START-GAP1/DLC1 have
focused on the so-called isoform 2. Low et al. have recently identified a new isoform of START-
GAP1/DLC1, isoform 4 (DLC1-i4), using 5’-RACE method [50]. This novel isoform encodes a
1,125-amino acid protein with distinct N-terminus as compared with other three isoforms.
Similar to them, DLC1-i4 is expressed ubiquitously in normal tissues and immortalized normal
epithelial cells, suggesting a role as a major START-GAP1/DLC1 transcript. Differential
expression of the four START-GAP1/DLC1 isoforms, however, is found in tumor cell lines:
Isoform 1 (the longest isoform) and isoform 3 (short and probably nonfunctional) share a
promoter and are silenced in almost all cancer and immortalized cell lines, whereas isoform 2
and isoform 4 utilize different promoters and are frequently downregulated. Isoform 4 is
significantly downregulated in multiple carcinoma cell lines, including nasopharyngeal,
esophageal, gastric, breast, colorectal, cervical and lung carcinomas. Ectopic expression of
DLC1-i4 suppresses tumor cell colony formation. Differential expression of the isoforms
suggests interplay in modulating the complex activities of START-GAP1/DLC1 during
carcinogenesis.
There are two additional members of the START-GAP/DLC family. START-GAP2/DLC2 (or
STARD13) gene is located on chromosome 13q12 [51] and START-GAP3/DLC3 (or STARD8/
KIAA0189) gene is located on the X chromosome at q13 band [31, 52]. The START-GAP2/
DLC2 encodes a 1,113-amino acid protein with a molecular mass of 125 kDa, whereas the
protein product of the START-GAP3/DLC3 transcript has 1,103 amino acids with a molecular
mass of 121 kDa. START-GAP2/DLC2 has a broad tissue distribution, with the highest levels
in the brain, heart and liver [15, 53]. Human START-GAP2/DLC2 protein shares 51% identity
and 64% similarity to human START-GAP1/DLC1 at the level of the amino acid sequence [51].
Introduction of human START-GAP2/DLC2 into mouse fibroblasts suppress Ras signaling and
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cell transformation in a GAP dependent manner, suggesting the role of START-GAP2/DLC2
for growth suppression and carcinogenesis [51].
START-GAP3/DLC3 is also detected in a variety of human tissues with high abundance in the
lung, kidney and placenta [53].
Following the findings of dysregulation of the START-GAP1/DLC1 gene function in a variety
of solid tumors, downregulation of START-GAP2/DLC2 and START-GAP3/DLC3 genes was
also shown to be involved in human cancer development.
START-GAP2/DLC2 was found to be downregulated in breast, lung, ovarian, renal, uterine,
gastric, colon, rectal, and liver tumors [15, 52, 54]. The comparison of START-GAP1/DLC1 and
START-GAP2/DLC2 gene expression in the same cell lines revealed that START-GAP2/DLC2
is more frequently downregulated than START-GAP1/DLC1 in HCC cell lines [15]. Moreover,
the overexpression of START-GAP2/DLC2 suppresses cell proliferation, motility and anchor‐
age-independent growth in the human hepatoma cell line, HepG2 [55]. START-GAP2/DLC2
was also reported to have an inhibitory effect on the growth of breast cancer cells in vitro [56].
Decreased START-GAP3/DLC3 expression in primary tumors from kidney, lung, uterine,
ovary and breast has been reported [52]. Kawai et al. have demonstrated that START-GAP3/
DLC3 serves as a GAP for both RhoA and Cdc42 in in vitro assays. Furthermore, the overex‐
pression of START-GAP3/DLC3 in HeLa cells disrupts actin stress fibers and changes cell
morphology in a GAP-dependent manner [31]. Ectopic expression of START-GAP3/DLC3 in
human breast and prostate cancer cell lines inhibits cell proliferation, colony formation and
growth in soft agar [52].
The structures of the three human START-GAP/DLC transcripts are depicted in Figure 2.
Figure 2. Schematic representation of the START-GAP/DLC family proteins. Each member of the family comprises of
three distinct domains, namely the sterile α motif (SAM), RhoGAP (GAP) domain and START (steroidogenic acute regu‐
latory protein (STAR)-related lipid transfer) domain.
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2.2. Gene knockout studies of START-GAP/DLC proteins
Using a mouse model a gene knockout study of START-GAP1/DLC1 has been carried out [57].
The mouse START-GAP1/DLC1 gene was inactivated by homologous recombination. Mice
heterozygous for the targeted allele were phenotypically normal, but homozygous mutant
embryos did not survive beyond 10.5 days postcoitum. Cultured fibroblasts from START-
GAP1/DLC1-deficient embryos displayed alterations in the organization of actin filaments and
focal adhesions [57]. In addition, a gene knockdown of START-GAP1/DLC1 in the background
of c-myc overexpression promotes the formation of liver tumors [58].
Although the START-GAP1/DLC1 gene deficient mice were embryonic lethal, deletion of the
START-GAP2/DLC2 gene from mice resulted in survival to adulthood, indicating that the gene,
unlike the START-GAP1/DLC1 gene, was dispensable for embryonic development [59].
Neither did the authors observe a higher incidence of liver tumor formation in the START-
GAP2/DLC2 gene knockout mice. Nevertheless, they reported smaller phenotype with less
formation of adipose tissue [59].
To the best of our knowledge, no reports describing the gene knockout study of the START-
GAP3/DLC3 gene are currently available.
2.3. Homologs of the START-GAP/DLC family
As mentioned earlier, there are homologs of the mammalian START-GAP/DLC family proteins
in invertebrates in the BLAST database. A Drosophila ortholog of START-GAP1/DLC1,
Crossveinless-c (Cv-c or RhoGAP88C), was identified in search for genes that regulate Drosophi‐
la morphogenesis [60]. The function of Cv-c has been revealed to be a key regulator for
unidirectional growth of dendritic branches of the fly via downregulating the activity of Rho1,
the Drosophila Rho GTPase [61]. In the Cv-c mutant, two subclass of multidendritic sensory
neurons formed dorsally directed branches; however, dendritic branches had a difficulty in
growing along the anterior–posterior (A–P) body axis, suggesting that Cv-c contributes to
sprouting and subsequent growth of the A–P-oriented branches through negative regulation
of Rho1 [61]. Thus Cv-c plays a key role in directional dendritic growth presumably via its
RhoGAP activity, localizing the GAP activity to sites undergoing cytoskeleton rearrangements
during morphogenesis.
3. Structure and function of the domains
The START-GAP/DLC family proteins are composed of multi-domain structures. START-
GAP/DLC proteins have three distinct domains: The sterile α motif (SAM) localized at its N-
terminus, a conserved RhoGAP (GAP) domain in the middle and the steroidogenic acute
regulatory (StAR)-related lipid transfer (START) domain at the C-terminus [51-53]. (Figure 2)
Although the START-GAP/DLC family proteins contain a potential lipid-binding START
domain, the proteins are produced in soluble forms. The intracellular localization of these
proteins, therefore, is determined by their specific interactions with target proteins resided at
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various cellular structures. Each domain of the START-GAP/DLC family proteins may
contribute to different subcellular localization patterns.
3.1. The GAP domain
The biological activity of START-GAP1/DLC1 is mainly executed by the GAP domain
(~150-200 amino acid), which promotes the hydrolysis of GTP bound to the Rho GTPases. This
catalytic activity is mediated by the ‘arginine-finger’ present in the GAP domain [62]. START-
GAP1/DLC1 and START-GAP3/DLC3 contain a conserved ‘arginine-finger’ at position 677
and 688, respectively [52, 53]. In in vitro assays both the full-length START-GAP1/DLC1 and
the isolated GAP domain reveal activity on RhoA, RhoB and RhoC, to a lesser extent on Cdc42,
and no activity on Rac1 [17, 32, 63]. By inactivating these small GTPases, START-GAP1/DLC1
affects cell morphology and control actin cytoskeletal remodeling [22, 23]. Similar to START-
GAP1/DLC1, both START-GAP2/DLC2 and START-GAP3/DLC3 contain a RhoGAP domain
and exhibit the GAP activity for RhoA and Cdc42 but not Rac1 in vitro [31, 32, 51].
3.2. The sterile α motif (SAM)
The SAM domain (~70 amino acids) has been found in signaling proteins (e.g., p53 related
proteins p73 and p63, Eph-related tyrosine kinases and Ets transcription factors) [64, 65]. The
SAM domain is thought to act as a protein interaction module via homo- or hetero-oligome‐
rization with other SAM domains [64]. As an example, the EphA2 receptor that plays key roles
in many physiological and pathological events including cancer has the SAM domain.
Recently, a structural study of the EphA2 receptor SAM domain has validated structural
elements relevant for the heterotypic SAM-SAM interactions: two SAM domains interact with
a head-to-tail topology characteristic of several SAM-SAM complexes [66]. The SAM domain
even interacts with RNA [67].
Structural studies of the SAM domain of START-GAP2/DLC2 have suggested that it binds to
lipids such as phosphatidylglycerol [68]. Nevertheless, we know little about exact roles of the
SAM domain in START-GAP/DLC function. Kim et al. have shown that the expression of the
amino-terminal domain of START-GAP1/DLC1 acts as a dominant negative and profoundly
inhibits cell migration by displacing endogenous START-GAP1/DLC1 from focal adhesions
[69]. The SAM domain of START-GAP1/DLC1 may serve as an autoinhibitory domain for
intrinsic RhoGAP catalytic activity. Eukaryotic elongation factor-1A1 (EF1A1) was found to
be a target of the SAM domain of START-GAP1/DLC1 [70]. EF1A1 is involved in protein
synthesis [71] and also in transporting β-actin mRNA [72]. EF1A1 is a regulator of cell growth
and the cytoskeletal network controlling the actin network through its G-actin-binding activity
[73], F-actin-bundling activity [74] and by stabilizing microtubules [75]. EF1A1 is overex‐
pressed in various human cancers, including pancreas, lung, prostate, breast and colon cancers
[71]. The SAM domain of START-GAP1/DLC1 adopts a four-helix fold similarly to the SAM
domain of START-GAP2/DLC2, but it utilizes a unique motif on a hydrophobic surface to bind
directly to EF1A1 [70]. Importantly, the SAM domain is necessary for START-GAP1/DLC1 to
translocate EF1A1 to the membrane periphery and ruffles upon fibroblast growth factor
stimulation, acting as an auxiliary oncogenic switch to the GAP domain [70].
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3.3. The START domain
The START domain (~210 amino acids) is a well-conserved lipid binding domain, which is
primarily found in proteins that transfer lipids between organelles and are involved in lipid
metabolism as well as in modulation of signaling events involved in lipid processing [76, 77].
The mammalian START domain protein family is well characterized and is composed of 15
members that are classified into 6 subfamilies based on the sequence and ligand specificity:
STARD1/3 and STARD4/5/6 subfamilies bind cholesterol and oxysterols, STARD2 (PCTP:
phosphatidylcholine transfer protein)/7/10/11(CERT: ceramide transfer protein) subfamily
binds phospholipids and ceramides/sphingolipids, STARD14 binds possibly fatty acids. They
all may have roles in non-vesicular lipid transport. STARD14/15 subfamily consists of proteins
with the thioesterase activity such as the Acyl-CoA thioesterase (ACOT) family proteins. The
START-GAP/DLC family proteins fall into the STARD8/12/13 subfamily [76, 77]. Lipid binding
properties of START-GAP1/DLC1 (STARD12), START-GAP2/DLC2 (STARD13) and START-
GAP3/DLC3 (STARD8) have not well characterized yet.
Among these proteins, STARD1 (or steroidogenic acute regulatory protein, StAR) and STARD3
(or metastatic lymph node 64 kDa protein, MLN64) appear to be the most well characterized
[78]. Both STARD1 and STARD3 bind cholesterol [79], and are also known to play a role in
lipid transport into mitochondria [80, 81]. In particular, STARD1 localizes to the mitochondria
and stimulates the translocation of cholesterol from the outer to the inner mitochondrial
membranes [79]. It has been suggested that STARD1 is an essential component in steroid
hormone production in steroidogenic cell [82, 83]. It is noteworthy, therefore, that START-
GAP2/DLC2 has been found to localize in mitochondria and was found in proximity to the
lipid droplets through the START domain [84]. Future research is required in order to establish
the lipid ligand of the START domain of START-GAP2/DLC2 and clarify whether the START
domain plays a role in mitochondrial lipid transport. START-GAP2/DLC2 also mediates
ceramide activation of phosphatidylglycerolphosphate (PGP) synthase and drug response in
Chinese hamster ovary cells [85].
The  crystal  structures  for  the  START  domains  of  human  STARD3/MLN64  (PDB  entry:
IEM2)  [86]  and murine  STARD4 (PDB entry:  1JSS)  [87]  were  the  first  to  be  solved and
showed  an  α-β  helix-grip  fold  with  a  nine-stranded  anti-parallel  β-sheet  forming  a  U-
shaped hydrophobic  cleft  that  binds  the  ligand and is  flanked by N-  and C-terminal  α
helices. The C-terminal α helix is proposed to serve as a ‘cap’ to the ligand-binding site,
with lipid access to the binding pocket requiring a conformational change in the START
domain and movement of the C-terminal helix. To date, the crystal structures for a limited
number of the START domain-containing proteins were solved: human STARD1/StAR (PDB
entry:  3P0L)  [88],  human STARD5 (PDB entry:  2R55)  [88],  human STARD2/PCTP (PDB
entry: 1LN1) [87], STARD11/CERT (PDB entry: 2E3R) [89], human STARD13/START-GAP2/
DLC2  (PDB  entry:  2PSO)  [88]  and  human  STARD14  (PDB  entry:  3FO5)  [88].  The  data
confirm  the  basic  helix-grip  fold  structure  across  the  five  mammalian  subfamilies  that
defines this family of proteins [88].
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3.4. The FAT region
Between the SAM and GAP domains there is a long unstructured region (~190 amino acids)
termed the FAT (focal adhesion targeting) region, due to the fact that its presence deter‐
mines of focal adhesion localization of the START-GAP/DLC proteins [27]. START-GAP1/
DLC1, START-GAP2/DLC2 and START-GAP3/DLC3 are recruited to focal adhesion sites
via their FAT sequence, which binds to the Src homology 2 (SH2) domains of focal adhesion
proteins and interacts with tensins [32,  43,  90].  The same region of START-GAP1/DLC1,
however, has been found to possess the ability to interact with the PTB domain of tensin2
[30,  91,  92]  and  tensin1  [43].  The  role  of  the  interaction  with  the  PTB  domain  in  the
localization of START-GAP1/DLC1 to focal adhesions remains controversial and requires
further  investigation.  Using  pull-down  assay,  Kawai  et  al.  reported  the  interaction  be‐
tween the other members of the START-GAP/DLC family, START-GAP2/DLC2 and START-
GAP3/DLC3, and tensin2 PTB [30].
Since the START-GAP/DLC family proteins are rich in serine residues, especially in their
FAT regions, it is natural to propose that these proteins could be phosphorylated by the
AGC (protein kinases A, G, and C) family protein kinases. Indeed, a numerous potential
phosphorylation  motifs  by  these  kinases  can  be  found  in  the  START-GAP/DLC  family
proteins. Protein kinase B (PKB or Akt) is among the member of the kinase family. Since
PKB/Akt plays an essential role in the actions of growth factors as well as the regulation
of many other cellular processes, such as apoptosis and anoikis, neuronal development and
degeneration, and the cell cycle [93], its involvement in function of the START-GAP/DLC
family proteins is argued [94].
Hers et al. have demonstrated that Ser322 in the FAT region of rat START-GAP1/DLC1 is
phosphorylated upon insulin stimulation of intact cells and that this site is directly phos‐
phorylated in vitro by PKB/Akt and ribosomal S6 kinase (RSK1), another member of the AGC
family of protein kinases [95], suggesting the phosphorylation via both the PKB/Akt and
MAPK kinase (MEK)/extracellular signal-regulated kinase (ERK)/RSK pathways by growth
factors. In other words, this site has the potential to integrate the activities of two different
signal transduction pathways in a manner dependent on the cellular context. As Ser322 falls
within the FAT region, its phosphorylation may be involved in regulating the targeting of
STASRT-GAP1/DLC1 to focal adhesions. However, despite the profound morphological
changes, both S322A and S322D mutants showed similar localizations to focal adhesions as the
wild-type STASRT-GAP1/DLC1. The function of the phosphorylation in signaling events
downstream of PKB/Akt, such as GLUT4 translocation, the activation of RhoA effectors and
cellular transformation, therefore awaits further studies.
A recent report by Ko et al. [96] has also postulated a central role of PKB/Akt phosphorylation
of human START-GAP1/DLC1 in the regulation of its tumor suppressive activity, but it argues
against the results obtained from the previously-mentioned study on rodent STASRT-GAP1/
DLC1. Although human START-GAP1/DLC1 has three characteristic phospho-PKB/Akt
substrate motifs, the authors showed that only Ser567 was phosphorylated by PKB/Akt. Only
active PKB/Akt was able to interact with STASRT-GAP1/DLC1. Since phosphorylated START-
GAP1/DLC1 forms a more stable interaction with PKB/Akt, there seems to be a cooperative
START-GAP/DLC Family Proteins: Molecular Mechanisms for Anti-Tumor Activities
http://dx.doi.org/10.5772/55268
177
increase in binding. Furthermore, Ko et al. showed that unphosphorylated START-GAP1/
DLC1 is sufficient to suppress proliferation and anchorage-independent cell growth. Using a
ras transformed, p53-deficient murine hepatoma line, the authors demonstrated that only wild-
type START-GAP1/DLC1 or a phosphorylation-dead mutant (S567A) was able to inhibit tumor
formation in nude mice, whereas the S567D mutant, simulating constitutive phosphorylation,
did not inhibit tumor growth. PKB/Akt, suggesting that all START-GAP/DLC family members
may share common mechanisms of post-translational regulation, also phosphorylated human
START-GAP2/DLC2 in the corresponding motif.
The central region of START-GAP1/DLC1 containing the FAT region was reported to target
caveolae by interacting with caveolin-1 [28, 92].
4. Regulation of intracellular localization
Generally, members of the START-GAP family, START-GAP1/DLC1, START-GAP2/DLC2
and START-GAP3/DLC3, START-GAP/DLCs do not localize evenly in the cytoplasm. Rather,
they are localized in the specialized place in intracellular spaces. All three members are
localized to focal adhesions of attached cells. A conserved region among them (the FAT region),
responsible for targeting to focal adhesions, has now been identified. It is now established that
the tensin family, which is the major component of the focal adhesion complex, is responsible
for recruiting the START-GAP/DLC family proteins to focal adhesions. Nevertheless, many
proteins are now revealed to interact with START-GAP/DLCs. Vinculin, another member in
the focal adhesion complex, can also interacts with the START-GAP/DLC family proteins. In
addition, PLCδ1 interacts with all three isoforms of START-GAP/DLCs and make a molecular
complex in lipid rafts upon stimulation with extracellular stimuli. Moreover, 14-3-3 binds to
START-GAP1/DLC1. Binding of 14-3-3 proteins often sequesters the target protein in a
particular subcellular compartment and the release of 14-3-3 proteins then allows the target to
be relocated. Since START-GAP1/DLC1 has a nuclear localization signal (NLS) sequence and
found in the nucleus, it is suggested that it also interacts with importins.
Thus expected function of the START-GAP/DLC family proteins varies from one cell type to
next, depending on the spatiotemporal regulation according to the binding proteins. Never‐
theless, as a whole, they regulate cell shapes and motility via remodeling of actin cytoskeleton.
4.1. Focal adhesion targeting via interaction with tensin and vinculin
START-GAP1/DLC1 is localized in focal adhesions via the FAT region located in its N-terminal
half and interacts with tensin family proteins, that constitutes focal adhesion components.
Evidences that the interaction between START-GAP1/DLC1 and tensin2 occurs in a PTB
domain-dependent manner have been provided. It was revealed that FAT3, the third subre‐
gion of the FAT region divided into five (39 amino acids), binds directly to the PTB domain of
tensin2 [30]. This interaction does not require protein phosphorylation, since the interaction
was detected with proteins expressed in bacterial expression system.
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START-GAP2/DLC2 and START-GAP3/DLC3, as well as STRT-GAP1/DLC1, bind to the PTB
domain of tensin2, presumably due to the presence of highly conserved residues in the center
of FAT3. Deletion of this sub-region abrogates the interaction with the tensin PTB domain. The
tensin2 PTB domain seems to determine the subcellular localization of FAT3. Nevertheless,
our study with deletion mutants revealed that FAT3 is essential but not sufficient for the focal
adhesion localization of START-GAP1/DLC1. These results suggest that the interaction
between the tensin PTB domain and FAT3 contributes to START-GAP1/DLC1 localization but
only partially. Other factors could affect the START-GAP1/DLC1 localization.
Figure 3. START-GAP1/DLC1 contributes to at least two signaling pathways. START-GAP1/DLC1 consists of about 11
hundred amino acids (for rat: 1,083 and for human: 1, 093) and contain the sterile α motif at the N-terminus, which is
known to function in protein-protein interaction. In the C-terminal half there are “GAP domain” followed by the
START domain, which is generally thought as a lipid binding or transfer domain. The GAP domain shows a GTPase-
activating function, specific for Rho family GTPases, RhoA and Cdc42 but not Rac1 [31], converting “the active, GTP-
bound form” to “the inactive, GDP-bound form.” The GAP activity of START-GAP1/DLC1 therefore may be implicated
in control of the cytoskeleton, cell polarity and cell migration. As for phosphoinositide signaling, one of the down‐
stream effectors of RhoA is PIP5K that generates PtdIns(4,5)P2. So by inhibition of activated Rho, PtdIns(4,5)P2 genera‐
tion is expected to be reduced. The C-terminal half of START-GAP1 is responsible for stimulation of PLCδ1 and breaks
down PtdIns(4,5)P2. This not only causes the generation of two second messengers, Ins(1,4,5)P3 and diacylgrycerol, but
also alters the activity of several PtdIns(4,5)P2-dependent actin-regulating proteins. As a whole, in microenvironment
surrounding active START-GAP1/DLC1, RhoA and Cdc42 are inacitvated and a loss of PtdIns(4,5)P2 is expected. The
region between the SAM and GAP domains is rich in serine residues and does not fall on any known protein domains
and has been thought to form disordered conformation.
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Amino acid sequence of START-GAP3/DLC3 contains a segment similar to the START-GAP1/
DLC1 tensin binding site (353STYDNL358) and full-length START-GAP3/DLC3 was shown to
bind the SH2 and PTB domains of tensin1 [43].
We noticed that tensin2 does not always colocalize with START-GAP1/DLC1 and that this
interaction was insufficient for targeting START-GAP1/DLC1 to focal adhesions. We thereby
explored if there is another molecule that interacts with START-GAP1/DLC1 by the GST pull-
down assay using GST-START-GAP1/DLC1 transfected HeLa cells. As a result, we found that
START-GAP1/DLC2 can bind with the C-terminus (730-1066) of vinculin. Moreover, START-
GAP1/DLC1 and vinculin were found colocalized in foal adhesions. The domain in START-
GAP1/DLC1 required for interaction with vinculin was narrowed down to residues 460-470
including an LD motif, a motif in paxillin required for interaction with vinculin. A deletion
mutant and point mutants of this motif were fully localized to focal adhesions, although they
lost binding ability to vinculin. It is likely that when START-GAP1, vinculin and tensin2 form
a stable complex, they are localized to focal adhesions.
PtdIns(4,5)P2 has an important role in regulating cytoskeleton assembly by inducing confor‐
mational changes in actin binding proteins such as vinculin and talin [97]. Thus, START-GAP1/
DLC1 could influence cytoskeletal dynamics by altering local PtdIns(4,5)P2 levels by activating
PLCδ1 in the vicinity of focal adhesions as well as by regulating Rho GTPase activity there.
4.2. Raft localization via interaction with PLCδ1
The C-terminal region of START-GAP1/DLC1 covering the GAP and START domain is known
to interact with PLCδ1, enhancing its activity [22]. Although START-GAP1/DLC1 binds with
PLCδ1, it is not usually localized at the plasma membrane where PLCδ1 targets itself through
its PH domain under unstimulated conditions.
Caveolae are plasma membrane domains that appear as flask-shaped invaginations at the cell
surface and are enriched in cholesterol and sphingolipids. Yamaga et al. have shown that
endogenous START-GAP1/DLC1 was found to sediment with caveolin-1 in low density
cholesterol-rich membrane fractions [28], and both endogenous and exogenous START-GAP1/
DLC1 were co-immunoprecipitated with caveolin-1 [28, 92]. Since multiple functions have
been proposed for caveolae [98] and caveolin-1 has been found in membrane subdomains other
than caveolae, including focal adhesions [98] the physiological significance of the interaction
between START-GAP1/DLC1 and caveolin-1 requires further investigation.
In their previous study [28], Yamaga et al. provided supportive evidences for START-GAP1/
DLC1 localization in caveola, which is cholesterol-enriched membrane microdomain, using an
expression system of GFP-tagged proteins, an immunoprecipitation assay and a sucrose
density gradient centrifugation analysis of cell lysates. GFP-tagged START-GAP1/DLC1 was
observed as patch-like structures at the cell surface and in the cytoplasm of attached cells. The
patches were dependent on the levels of the membrane cholesterol and co-localized with
caveolin-1. START-GAP1/DLC1 interacts with caveolin-1 in vivo and is fractionated into low-
density caveolin-enriched membrane fractions. These results support the idea that START-
GAP1/DLC1 is targeted to caveolae via binding to caveolin-1. Yamaga et al. also found the C-
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terminal half of START-GAP1/DLC1 was responsible for its patch-like distribution. The
authors found amino acid sequences that resemble putative caveolin-binding motifs
(ΦXΦXXXXΦ, ΦXXXXΦXXΦ or ΦXΦXXXXΦXXΦ), where Φ is an aromatic residue and X is
any amino acid [99] in the N-terminal region (14WLRVTGFPQY23 and
93WTFQRDSKRWSRLEEFDVF111) and in the GAP domain (690YVNYEGQSAY699 and
725FLQIYQY731) of START-GAP1/DLC1. Since GFP-tagged START-GAP1/DLC1–534ΔC does
not seem to reside in caveolin-1-containing membranes, the sequences in the N-terminal region
may not function as caveolin-binding motifs. Either (or both) the sequence(s) in the GAP
domain, however, could be important for caveolin-1 binding and therefore responsible for the
distribution of START-GAP1/DLC1. It is therefore possible that the RhoGAP domain of
START-GAP1/DLC1 contributes not only to the catalytic activity but also to the intracellular
localization of START-GAP1/DLC1. The exact roles of the N-terminal region have to be
clarified. GFP-tagged START domain was also observed as patches, but unlike GFP-tagged
full-length protein or GFP-tagged GAP domain, it was just partially co-localized with caveo‐
lin-1. The patch-like localization of GFP-tagged START domain was similar to the distribution
of cholesterol visualized by filipin, a fluorescent molecule that specifically binds to free
cholesterol. The result suggests that the START domain can associate with cholesterol but it is
not sufficient to recruit START-GAP1/DLC1 to caveolin-1-enriched membrane microdomains.
Recruitment and activation of PLCδ1 in lipid rafts by a muscarinic agonist was examined using
PC12 cells [24]. Sucrose density gradient centrifugation analyses of cell lysates revealed that
only a small amount of PLCδ1 was recovered in low-density membrane fractions. The amount,
however, significantly increased when cells were treated with a muscarinic agonist carbachol.
Immunoprecipitation studies demonstrated that carbachol also enhanced the interaction
between PLCδ1 and START-GAP1/DLC1, which is constitutively localized in lipid rafts. The
PH domain of PLCδ1 is likely responsible for the interaction. Since carbachol elevates intra‐
cellular Ca2+levels in PC12 cells, Yamaga et al. next examined whether a rise of intracellular
Ca2+ levels participates in the carbachol-induced raft recruitment of PLCδ1. After treatment
with a Ca2+ ionophore ionomycin PLCδ1 was also translocated to lipid rafts in PC12 cells.
Chelating extracellular Ca2+ by EGTA did not inhibit the carbachol-induced translocation of
PLCδ1 to lipid rafts, whereas treatment of cells with thapsigargin to block the intracellular
Ca2+ mobilization inhibited its translocation. These results suggest that PLCδ1 is recruited to
lipid rafts and binds to preexisting START-GAP1/DLC1 in Ca2+ dependent manner, and this
process can be triggered by external stimuli activating GPCRs (Figure 4).
Although the physiological function and significance of START-GAP1/DLC1 in caveolar
localization remain unclear, it appears that caveolae are one of the compartments whereby
START-GAP1/DLC1 may exhibit its tumor-suppressive role and possibly vasoregulatory role
which will be mentioned in Section 7, and affect the cytoskeletal reorganization by its RhoGAP
activity.
4.3. START-GAP2/DLC2 localization in mitochondria
Apart from focal adhesion localization, START-GAP/DLCs could be localized in mitochondria.
Ng et al. has disclosed that START-GAP2/DLC2 is targeted to mitochondria through the
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START domain using Huh-7 hepatoma cells [84]. They could observe the expression of ectopic
START-GAP2/DLC2 in the cytoplasm especially in a punctate structure, suggesting that
START-GAP2/DLC2 was concentrated in cytoplasmic speckles. It is noteworthy that the
localization patterns of full-length START-GAP2/DLC2, START-GAP2/DLC2-ΔSAM lacking
the N-terminal SAM domain and START-GAP2/DLC2-START, that consists of only from the
START domain were very similar, indicating that the START domain is responsible for the
intracellular localization. Analysis of the amino acid sequence has revealed that no noticeable
localization signal in the START domain. START-GAP2/DLC2-START was in dot-like
structure throughout the cytosol, although some cells showed aggregates in the perinuclear
region, while START-GAP2/DLC2-ΔSTART, a mutant lacking the START domain, was found
to distribute homogenously in the cytoplasm. Notably, almost all START-GAP2/DLC2 signals
overlapped those of mitochondria, but not all mitochondria were targeted by START-GAP2/
DLC2. They also biochemically fractionated mitochondrial fraction from myc-tagged START-
GAP2/DLC2 expressed Huh-7 cells and found that it was found in both the cytoplasmic and
mitochondrial fraction. Taken together, the START domain plays a pivotal role in intracellular
localization and function of START-GAP2/DLC2. Whether these results could also apply for
endogenous START-GAP1/DLC1 or START-GAP3/DLC3 in other cell types awaits future
experiments.
4.4. START-GAP2/DLC2 localization around lipid droplets
In addition to demonstrate the mitochondrial localization of START-GAP2/DLC2, Ng et al.
also examined whether START-GAP2/DLC2 and/or the START domain of START-GAP2/
DLC2 can interact with intracellular lipids [84]. Since localization pattern of START-GAP2/
DLC2 and its START domain are very similar, they examined whether lipophilic dyes such as
Nile red and Sudan III overlap with signal of the START domain of START-GAP2/DLC2. The
speckles containing the START domain were localized around the lipid droplets stained by
Nile red. Nevertheless, the two signals did not overlap substantially with each other, despite
that a major portion of the START domain was found to be in proximity to the lipid droplets.
The authors suggested that the START domain of START-GAP2/DLC2 likely serves a lipid
related function in the cell and it targets START-GAP2/DLC2 to areas proximal to the lipid
droplets [84].
4.5. START-GAP1/DLC1 localization in the nucleus
Recently, using lung carcinoma cells Yuan et al. showed that START-GAP1/DLC1 harbors a
functional bipartite nuclear localization signal (NLS) in serine-rich domain in the FAT region,
which works together with the GAP domain to mediate START-GAP1/DLC1 nuclear import
and subsequent apoptosis [38]. The potential NLS sequence was found as amino acids
415RRENSSDSPKELKRRNS431 including a pat7 NLS spanning residues 423PKELKRR429 [100]. A
deletion mutant START-GAP1/DLC1-Δ372 lacking the N-terminus 372 amino acids accumu‐
lates in the nucleus, suggesting the presence of nuclear export signal (NES) in this region,
whereas mutants with disruption of this NLS sequence could only localize in the cytosol.
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The function of START-GAP1/DLC1 in the nucleus remains to be defined. Some Rho GTPases
have C-terminal polybasic region that could be function as an NLS [101]. Therefore these
GTPases may serve as substrates for START-GAP1/DLC1 in the nucleus. In the nucleus
START-GAP1/DLC1 may also interact with non-GTPase substrates such as PLCδ1 [22], which
is under nuclear import-export equilibrium and accumulate in the nucleus under specific
phases of the cell cycle [102, 103] or extracellular stimuli that causes aberrant increase in
intracellular Ca2+ [103-106]. Nuclear translocation of START-GAP1/DLC1 was proposed to be
associated with apoptosis by a yet unknown mechanism [38].
START-GAP1/DLC1 interacts with 14-3-3 proteins, resulting inhibition of the GAP activity and
block nucleo-cytoplasmic shuttling [100]. In GST pull-down assays, START-GAP1/DLC1
interacted with all 14-3-3 isoforms except 14-3-3σ. The other six 14-3-3 isoforms are ubiqui‐
tously expressed, readily form homo- and heterodimers, and could therefore potentially
participate in the regulation of START-GAP1/DLC1 function. 14-3-3 proteins often regulate
cellular processes by modulating target protein localization. The pat7 NLS spanning residues
of START-GAP1/DLC1, 423PKELKRR429, was demonstrated to be masked by phorbolester-
induced phosphorylation and the 14-3-3 interaction. Inactivation of this NLS by exchange of
critical arginine residues impaired but did not prevent nuclear import of START-GAP1/DLC1.
This suggests the presence of another NLS that contributes to START-GAP1/DLC1 nuclear
shuttling.
Taken together, it was suggested that START-GAP1/DLC1 functions both as a cytoplasmic and
nuclear tumor suppressor.
5. Negative regulation of carcinogenesis not dependent on the RhoGAP
activity
5.1. RhoGAP activity-dependent pathway
As mentioned earlier, the START-GAP/DLC family proteins may exert their suppressive
function by decreasing the levels of active, GTP-bound Rho proteins or inhibiting the GDP-
GTP cycling process, affecting cytoskeletal remodeling, cell shape, motility, proliferation and
apoptosis. Nevertheless, molecular mechanisms through which START-GAP/DLC family
proteins are capable of suppressing cell motility and cell growth are still unclear.
Holeiter et al. have shown that enhanced migration of cells lacking START-GAP1/DLC1 is
dependent on the Rho effector, Dia1, and does not require the activity of ROCK [107]. Leung
et al. provide evidence for a key mechanism through which the START-GAP/DLC family
proteins act as tumor suppressors [108]. In this study, the authors demonstrated that the
expression of START-GAP2/DLC2 is involved in the inactivation of the Raf/MEK/ERK/RSK
pathway, which is crucial for cell proliferation. This inhibitory activity of START-GAP2/DLC2
is attributed to RhoGAP function [108].
By binding to PLCδ1, START-GAP1/DLC1 enhances the hydrolysis of PtdIns(4,5)P2, which
interacts with a variety of actin regulatory proteins that affect the actin cytoskeleton [22, 23,
START-GAP/DLC Family Proteins: Molecular Mechanisms for Anti-Tumor Activities
http://dx.doi.org/10.5772/55268
183
28]. In addition to the PLCδ1 activation and the modulation of RhoGAP activities, proper focal
adhesion localization and interaction with tensins have been demonstrated to be essential for
the growth-suppression function of START-GAP1/DLC1 [43, 90, 92, 109].
START-GAP1/DLC1 overexpression induces a significant reduction of stress fibers and
filopodia, as well as membrane blabbing and cellular decomposition, nuclear condensation or
fragmentation in NCI-H358 cells known as highly sensitive cells to tumor suppression
functions of START-GAP1/DLC1 [110]. These effects were due to the collapse of actin cytos‐
keleton during apoptosis [111].
To overcome the embryonic lethality of homozygous START-GAP1/DLC1 knockdown [57],
Zender et al. combined in vivo RNAi and a ‘mosaic’ mouse model of HCC to address the
impact of the loss of START-GAP1/DLC1 on liver carcinogenesis [112]. Genetically modified
liver  progenitors  (p53−/−  cells  infected  with  a  retrovirus  expressing  c-myc  and  another
expressing a START-GAP1/DLC1 shRNA) were transplanted into the liver of syngenic mice
to assess their  ability to generate tumors in situ.  In contrast  to  control  shRNA, START-
GAP1/DLC1 shRNA accelerates  the formation of  liver  tumors,  which mimics  aggressive
HCC. Conversely,  reintroduction of START-GAP1/DLC1 in hepatoma cells co-expressing
oncogenic Ras results in a dramatic reduction of tumor growth in situ. This study demon‐
strates  that  START-GAP1/DLC1  loss,  when  combined  with  other  oncogenic  lesions,
efficiently promotes the development of HCC.
Activation of RhoA, and thereby of its downstream effector ROCK, is both necessary and
sufficient to promote HCC in vivo. Therefore, START-GAP1/DLC1, due to its RhoGAP activity,
is capable to antagonize the activities of RhoA and its downstream effectors in HCC [58, 113,
114]. Moreover, RhoA is required for tumorigenesis induced by the loss of START-GAP1/DLC1
and constitutively active RhoA mimics loss of START-GAP1/DLC1 in promoting HCC in the
‘mosaic’ mouse model [58].
START-GAP1/DLC1 was also implicated in tumor metastasis. The expression levels of START-
GAP1/DLC1 mRNA are significantly lower in highly invasive tumors than in less invasive
ones [115]. Restoration of START-GAP1/DLC1 expression in vitro reduces the migration and
the invasiveness of HCC cells [35, 41, 113]. This mechanism also seems to be dependent on
RhoGAP activity and its downstream effectors ROCK and MLC [42].
Finally, reexpression of START-GAP1/DLC1 in HCC cells downregulated the expression of
osteopontin and matrix metalloproteinase-9, which are found overexpressed in most primary
metastatic liver tumors [114]. START-GAP1/DLC1 restoration also suppresses the distant
dissemination of cells from subcutaneous tumors developing after inoculation of HCC cell
lines in mice. This process is also dependent on the RhoA activity and reorganization of actin
cytoskeleton in tumor cells [114].
5.2. RhoGAP activity-independent pathway
Angiogenesis is another form of cancer development. In addition to its direct effect via
activation of Rho pathway, START-GAP1/DLC1 is responsible for regulation of angiogenesis
in an indirect manner [116]. START-GAP1/DLC1 negatively regulates angiogenesis in a
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paracrine fashion. START-GAP1/DLC1 silencing promoted pro-angiogenic responses through
vascular endothelial growth factor upregulation, accompanied by the accumulation of
hypoxia-inducible factor 1 and its nuclear localization.
6. Stability of START-GAP/DLCs
Stability of proteins may also contribute to the expression levels of the START-GAP/DLC
family proteins. Generally, degradation of proteins is controlled by ubiquitination-dependent
and independent proteolysis. START-GAP1/DLC1 seems to be ubiqutinylated and processed
at least partly by ubiquitinylation-dependent proteasomal degradation [117]. Nevertheless,
the sites and the mode of ubiquitinylation (mono- or poly-) on the molecule are unclear. In
addition, a proinflammatory protein S100A10, a key cell surface receptor for plasminogen and
a regulator of proteolysis, was found to be a novel binding partner of START-GAP1/DLC1
[118]. S100A10 colocalizes with START-GAP1/DLC1 in the cytoplasm via interaction between
the C-terminus of S100A10 and the central domain of START-GAP1/DLC1, regulating tumor
cell invasion [118]. These results strongly suggest that proteolysis dependent on post-tran‐
scriptional modification of START-GAP1/DLC1 plays an important role in the regulation of
its tumor suppressive activity.
7. Possible roles of START-GAP1/DLC1 in the development of vascular
diseases
Recently, another potential role of START-GAP1/DLC1 in the pathogenesis of a human disease
has emerged. It has been known that the PLC activity with its effect on the regulation of
intracellular Ca2+ levels has potential roles in cardiac regulation. PLCδ1 activity has shown to
be enhanced in patients with coronary artery spasm, CSA (coronary spastic angina) [119,
120]. In this context, a new finding that START-GAP1/DLC1 protein levels and mRNA levels
in fibroblasts from Japanese patients with CSA were enhanced compared with levels in control
subjects is noteworthy [121]. The authors also found in the START-GAP1/DLC1 promoter
analysis, the -228G/A and -1466C/T variants found associated with CSA patients using 5’-
RACE method revealed the increase in luciferase activity [121]. The incidence of -228G-A was
more frequent in male patients with CSA than in male control subjects, suggesting that this
variant is a possible candidate responsible for upregulation of START-GAP1/DLC1 protein in
CSA. Thus, it was postulated that START-GAP1/DLC1 is up-regulated in patients with
coronary spasm, possibly by mutations in the promoter region, causing increased [Ca2+]i to
acetylcholine, and thereby seems to be related to enhanced coronary vasomotility.
As stated in the earlier section, START-GAP1/DLC1 plays two important roles in signaling
pathways: One of the dual functions is the ability to enhance the PtdIns(4,5)P2-hydrolyzing
activity of PLCδ1 and the other is the GAP activity specific for RhoA and Cdc42. The former
leads to both the protein kinase C-mediated pathway and Ca2+-dependent pathway, resulting
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in enhanced myosin light chain phosphorylation that plays an important role in the constrictor
response of the coronary artery smooth muscle to transmitters such as serotonin and histamine.
Homma and Emori showed that recombinant PLCδ1 catalyzes the hydrolysis of PtdIns(4,5)P2
in a Ca2+-dependent manner; in the presence of START-GAP1/DLC1, its activity is 5- to 10-fold
increased in the range of physiological Ca2+ concentration [22]. Thus, it is conceivable that
upregulation of START-GAP1/DLC1 protein observed in patients with CSA is responsible for
the high activity of PLCδ1. These results are consistent with the previous finding of the H257R
variant of PLCδ1, in which the conformational change is associated with upregulation of
PLCδ1 activity [120]. These characteristics seem to explain the pathogenesis of CSA in which
both the basal vascular tone and the vasoconstrictor response to the diverse stimuli were
enhanced. Previously, PLC activity was shown to positively correlate not only with basal
coronary artery tone but also with the maximal and averaged constrictor responses of the
coronary artery to acetylcholine [119]. This finding also suggests a critical role of START-GAP1/
DLC1 protein in the genesis of coronary spasm.
The START-GAP1/DLC1 protein has another function, a GAP activity for Rho GTPases.
Alterations in RhoA/ROCK pathway have been implicated in the development of a variety of
cardiovascular diseases, including hypertension, atherosclerosis, and cerebral and coronary
vasospasm [122, 123].
It was reported that the ROCK inhibitor fasudil attenuated the constrictor response of the
coronary artery to ACh and prevented the occurrence of chest pain in patients with CSA [124].
By its GAP activity, START-GAP1/DLC1 may antagonize the development of coronary spasm
like the ROCK inhibitor. On the other hand, Ca2+ mobilization induced by PLCδ1 activation
may upregulate Rho and ROCK in the vascular smooth muscle [125]. Thus, the role of START-
GAP1/DLC1 in the regulation of Rho is complicated, and the relation of START-GAP1/DLC1
to the genesis of coronary spasm via Rho activity remains to be determined.
The mechanisms of enhancement of START-GAP1/DLC1 promoter activity by the -228G/A
variant may be related to transcription factor SP because this variance causes loss of binding
to SP1 in its region [121]. Upregulation of START-GAP1/DLC1 protein in the coronary arteries
of CSA patients should be confirmed. It remains unclear whether upregulation of START-
GAP2/DLC2 or START-GAP3/DLC3 is associated with CSA.
Regarding the caveola localization of START-GAP1/DLC1, the recent report by Nuno et al.
that RhoA colocalization with caveolin-1 in caveolae regulates vascular contractions to
serotonin is of interest [126]. Caveolins are not only structural components of caveola micro‐
domains, but also regulate assembly and activation of a variety of receptors and signaling
molecules such as PtdIns(4,5)P2, glucose transporter 4 (GLUT4), epidermal growth factor
receptors (EGFR) and endothelial nitric oxide synthase (eNOS). Localization of RhoA to
caveolae versus noncaveolar lipid rafts differentially regulates its activation and contractions
to RhoA-dependent agonists with greater activation associated with its localization to
noncaveolar rafts. Presumably, translocalization of START-GAP1/DLC1 to caveolae by
agonists reported by Yamaga et al. [24, 28] may also contribute to modulate the activity of
RhoA/ROCK pathway in vascular cells.
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Figure 4. Roles of START-GAP1/DLC1 in a lipid raft/caveola and its possible involvement in the pathogenesis of coro‐
nary vasospasm. When G protein coupled receptors (GPCRs) such as muscarinic receptors are activated by agonists
they initially stimulate β-type PLC resulting in the production of Ins(1,4,5)P3 from PtdIns(4,5)P2. Ins(1,4,5)P3 binds to the
receptors (IP3R or ER Ca2+ pump) at the intracellular Ca2+ stores such as ER and mobilizes Ca2+ from the stores. PLCδ1 is
localized at the plasma membrane and in the cytosol in unstimulated cells, whereas START-GAP1/DLC1 is localized in
lipid rafts via binding with cholesterol (or with caveolin if the lipid rafts are caveolae). The agonist-induced primary
increase in Ca2+ recruits PLCδ1 into lipid rafts from other parts of the plasma membrane or from the cytosol by un‐
known mechanisms. PLCδ1 in the lipid rafts then binds START-GAP1/DLC1 to be activated in the presence of Ca2+, re‐
sulting in a robust hydrolysis of PtdIns(4,5)P2 that forms clusters in lipid rafts. Released Ins(1,4,5)P3 then empties the
internal Ca2+ stores via activation of IP3R followed by stimulation of TRP channels, a component of store-operated
channels (SOCs) to increase Ca2+ influx (secondary Ca2+). Thus the recruitment of PLCδ1 to rafts confers a general posi‐
tive feedback mechanism for phosphoinositide/Ca2+ signaling in the cells. START-GAP1/DLC1 also modulates the
RhoA/ROCK signaling pathway. Modified from [24].
8. Conclusion
The START-GAP/DLC family proteins are a group of Rho GTPases whose aberrant function
suggests dysregulation of numerous cell processes that can develop diseases such as cancers
and vascular spasm. Both in vitro and in vivo studies have provided strong evidence that
START-GAP/DLCs have roles in regulating actin cytoskeleton organization. Binding to tensins
and other molecules may target the RhoGAP activity of the START-GAP/DLCs to particular
subcellular domains. Accumulating reports indicate that the START-GAP/DLC proteins are
regulated in various ways at a genetic level by gene deletion, at an epigenetic level by the
aberrant promoter methylation, or at a cellular level by the regulation of localization and
stability. More information is required on the mechanisms responsible for these regulations,
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including post-translational modifications such as phosphorylation and ubiquitination. In
addition, dissection of the interacting partners of START-GAP/DLCs by proteomic analyses
will reveal detailed signaling pathways that regulate cell shape, motility and proliferation.
Future studies on the difference among START-GAP/DLCs may reveal which member of this
family plays a key role in individual types of cancer or in vascular abnormality and whether
restoration of the proper function of the START-GAP/DLCs is capable of restraining cell
transformation or abnormal signaling. These efforts would result in identification of the
member that becomes the subject of future studies as a potential drug target for therapy.
Nomenclature
CSA: cardiac spastic angina, DLC: deleted in liver cancer, GAP: GTPase activating protein,
HCC: hepatocellular carcinoma, Ins(1,4,5)P3: inositol 1,4,5-trisphospate (IP3), NLS: nuclear
localization signal, PLC: phosphoinositide-specific phospholipase C, PKB: protein kinase B,
PtdIns(4,5)P2: phosphatidylinositol 4,5-bisphosphate (PIP2), ROCK: Rho-kinase, START:
steroidogenic acute regulatory protein (STAR)-related lipid transfer
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